8-K: AbbVie Q3 Revenue Jumps 9.1%; Raises 2025 EPS Guidance

AbbVie reported strong third-quarter net revenues of $15.776 billion, an increase of 9.1%, and raised its full-year 2025 adjusted diluted EPS guidance.

Summary

• Third-quarter 2025 net revenues reached $15.776 billion, marking a 9.1% increase on a reported basis and 8.4% operationally.
• GAAP diluted EPS for the quarter was $0.10, an 88.6% decrease, while adjusted diluted EPS was $1.86, a 38.0% decrease, both impacted by $1.50 per share in acquired IPR&D and milestones expense.
• The immunology portfolio grew by 11.9% to $7.885 billion, driven by Skyrizi ($4.708 billion, +46.8%) and Rinvoq ($2.184 billion, +35.3%), offsetting a 55.4% decline in Humira to $993 million.
• Neuroscience portfolio revenues increased 20.2% to $2.841 billion, with strong contributions from Vraylar ($934 million, +6.7%), Botox Therapeutic ($985 million, +16.1%), and combined Ubrelvy and Qulipta ($642 million).
• Oncology portfolio revenues decreased 0.3% to $1.682 billion, primarily due to a 14.8% decline in Imbruvica to $706 million, partially offset by Venclexta and Elahere growth.
• Aesthetics portfolio revenues decreased 3.7% to $1.193 billion, with Botox Cosmetic down 4.9% to $637 million and Juvederm down 2.2% to $253 million.
• Full-year 2025 adjusted diluted EPS guidance was raised from $10.38 $10.58 to $10.61 $10.65, including a $2.05 per share unfavorable impact from year-to-date acquired IPR&D and milestones.
• The company announced a 5.5% increase in its quarterly cash dividend, from $1.64 to $1.73 per share, effective February 2026.

Sentiment

Score: 7

Explanation: The strong revenue growth, particularly from key immunology and neuroscience assets, and the raised full-year EPS guidance demonstrate robust operational performance and management confidence. While Q3 EPS saw a significant GAAP and adjusted decline, this was largely due to IPR&D expenses, which are often one-off. The dividend increase and pipeline advancements further support a positive outlook, despite the expected Humira decline and some softness in aesthetics.

Positives

• Strong overall net revenue growth of 9.1% reported and 8.4% operational to $15.776 billion.
• Immunology portfolio demonstrated robust growth of 11.9% to $7.885 billion, driven by Skyrizi (+46.8% to $4.708 billion) and Rinvoq (+35.3% to $2.184 billion).
• Neuroscience portfolio grew significantly by 20.2% to $2.841 billion, with strong performance from Botox Therapeutic (+16.1% to $985 million) and Qulipta (+64.1% to $288 million).
• Full-year 2025 adjusted diluted EPS guidance was raised to $10.61 $10.65, indicating increased confidence in future performance.
• Quarterly cash dividend increased by 5.5% to $1.73 per share, reflecting a strong commitment to shareholder returns.
• Multiple positive clinical trial results and regulatory approvals/submissions for key pipeline assets, including Rinvoq for updated UC/CD indication, alopecia areata and vitiligo, tavapadon for Parkinson's disease, and Botox for essential tremor.
• Strategic acquisitions of Capstan Therapeutics and Gilgamesh Pharmaceuticals' bretisilocin enhance the pipeline in autoimmune diseases and major depressive disorder.
• Significant capital investment in U.S. manufacturing, including a new $195 million API facility and a $70 million expansion at the Bioresearch Center, supporting long-term growth and innovation.

Negatives

• GAAP diluted EPS decreased significantly by 88.6% to $0.10, and adjusted diluted EPS decreased by 38.0% to $1.86, largely due to a $1.50 per share unfavorable impact from acquired IPR&D and milestones expense.
• Global Humira net revenues declined sharply by 55.4% to $993 million, reflecting ongoing biosimilar competition.
• Oncology portfolio experienced a slight decrease of 0.3% in reported net revenues, primarily due to a 14.8% decline in Imbruvica revenues to $706 million.
• Aesthetics portfolio revenues decreased by 3.7% to $1.193 billion, with Botox Cosmetic down 4.9% and Juvederm down 2.2%.
• The GAAP tax rate was exceptionally high at 73.7% for the quarter.

Risks

• Challenges to intellectual property.
• Competition from other products.
• Difficulties inherent in the research and development process.
• Adverse litigation or government action.
• Changes to laws and regulations applicable to the industry.
• Impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs.
• Other uncertainties and risks associated with global business operations.

Future Outlook

AbbVie raised its full-year 2025 adjusted diluted EPS guidance range from $10.38 $10.58 to $10.61 $10.65, which includes an unfavorable impact of $2.05 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2025. The company also announced a 5.5% increase in its quarterly cash dividend to $1.73 per share, beginning with the dividend payable in February 2026, reflecting confidence in its business strength and promising outlook.

Management Comments

• AbbVie continues to deliver outstanding results, with significant momentum across key areas of our portfolio.
• We are also making great progress advancing our pipeline and investing in innovation to support AbbVie's long-term growth.
• Based upon the strength of our business and its promising outlook, we are once again raising our quarterly cash dividend.

Industry Context

This announcement highlights AbbVie's successful navigation of the Humira patent cliff through robust growth in newer immunology assets like Skyrizi and Rinvoq, which are becoming major revenue drivers. The significant investment in R&D and strategic acquisitions of Capstan Therapeutics and Gilgamesh Pharmaceuticals demonstrate a commitment to pipeline diversification and long-term growth beyond its established blockbusters, particularly in autoimmune diseases, neuroscience, and oncology. The decline in aesthetics revenue, however, suggests some market softness or increased competition in that segment, contrasting with the strong performance in therapeutic areas.

Comparison to Industry Standards

• The rapid growth of Skyrizi (+46.8%) and Rinvoq (+35.3%) demonstrates AbbVie's successful strategy in replacing Humira's declining revenue, a challenge many pharmaceutical companies face when major patents expire. This performance is strong compared to peers struggling with similar patent cliffs.
• The significant investment in new manufacturing facilities ($195 million API facility, $70 million Bioresearch Center expansion) aligns with industry trends of strengthening supply chains and expanding capacity for biologics and complex molecules, ensuring future product availability.
• The acquisition of Capstan Therapeutics, focusing on in vivo CAR-T therapy for autoimmune diseases, positions AbbVie at the forefront of innovative cell therapy approaches, a high-growth area in biotech.
• The 5.5% dividend increase continues AbbVie's track record as an S&P Dividend Aristocrat, a benchmark for consistent shareholder returns, which is a strong signal of financial health and management confidence compared to many growth-focused biotech firms that do not pay dividends.

Legal Proceedings

• Litigation matters primarily include charges related to actual and potential settlements of litigation (mentioned in 2024 reconciliation, but no new specific details for 2025).

Stakeholder Impact

• Shareholders: Benefit from a 5.5% increase in the quarterly cash dividend and raised full-year adjusted EPS guidance, indicating strong returns and future profitability.
• Patients/Customers: Potential for new treatment options with FDA approvals for Rinvoq's updated indication, positive clinical trial results for Rinvoq in alopecia areata and vitiligo, tavapadon for Parkinson's disease, and Botox for essential tremor.
• Employees: Expansion of manufacturing facilities in North Chicago and Worcester suggests job creation and increased operational capacity.
• Investment Community: The strong performance of growth assets and strategic pipeline advancements provide a positive signal for long-term investment, despite short-term EPS impacts from IPR&D.

Next Steps

• Quarterly cash dividend of $1.73 per share payable on February 17, 2026, to shareholders of record as of January 16, 2026.
• New North Chicago API facility expected to be fully operational and serving patients by 2027.

Key Dates

Recommendation

Despite the significant GAAP and adjusted EPS decline in Q3 2025, which was primarily driven by a substantial, likely one-off, acquired IPR&D and milestones expense, AbbVie demonstrated strong underlying operational performance. Net revenues increased by 9.1%, fueled by exceptional growth in key immunology assets like Skyrizi (+46.8%) and Rinvoq (+35.3%), successfully offsetting the expected decline of Humira. The company's decision to raise its full-year 2025 adjusted diluted EPS guidance, coupled with a 5.5% dividend increase, signals strong management confidence in its diversified portfolio and robust pipeline. Strategic acquisitions and significant manufacturing investments further bolster long-term growth prospects. The temporary EPS dip due to IPR&D should not overshadow the fundamental strength and positive trajectory of AbbVie's core business and future innovation.

Keywords

AbbVie, ABBV, Q3 2025 Earnings, Financial Results, Pharmaceuticals, Biotechnology, Immunology, Neuroscience, Oncology, Aesthetics, Skyrizi, Rinvoq, Humira, Vraylar, Botox, Imbruvica, Venclexta, Elahere, EPS Guidance, Dividend Increase, Pipeline, Acquisitions, R&D, SEC Filing